166 related articles for article (PubMed ID: 8849228)
1. Susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to a new quinolone, trovafloxacin (CP-99,219).
Kenny GE; Cartwright FD
Antimicrob Agents Chemother; 1996 Apr; 40(4):1048-9. PubMed ID: 8849228
[TBL] [Abstract][Full Text] [Related]
2. Susceptibilities of Mycoplasma hominis, Mycoplasma pneumoniae, and Ureaplasma urealyticum to a new quinolone, OPC 17116.
Kenny GE; Cartwright FD
Antimicrob Agents Chemother; 1993 Aug; 37(8):1726-7. PubMed ID: 8215294
[TBL] [Abstract][Full Text] [Related]
3. Susceptibilities of Mycoplasma hominis and Ureaplasma urealyticum to two new quinolones, sparfloxacin and WIN 57273.
Kenny GE; Cartwright FD
Antimicrob Agents Chemother; 1991 Jul; 35(7):1515-6. PubMed ID: 1929320
[TBL] [Abstract][Full Text] [Related]
4. In vitro susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to sparfloxacin and PD 127391.
Waites KB; Duffy LB; Schmid T; Crabb D; Pate MS; Cassell GH
Antimicrob Agents Chemother; 1991 Jun; 35(6):1181-5. PubMed ID: 1929260
[TBL] [Abstract][Full Text] [Related]
5. In-vitro susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis and Ureaplasma urealyticum to clinafloxacin, PD 131628, ciprofloxacin and comparator drugs.
Cohen MA; Huband MD
J Antimicrob Chemother; 1997 Aug; 40(2):308-9. PubMed ID: 9302005
[No Abstract] [Full Text] [Related]
6. [In vitro activity of sparfloxacin against mycoplasmas].
Renaudin H; Bebear C
Pathol Biol (Paris); 1992 May; 40(5):450-4. PubMed ID: 1323094
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of trovafloxacin compared to those of five antimicrobials against mycoplasmas including Mycoplasma hominis and Ureaplasma urealyticum fluoroquinolone-resistant isolates that have been genetically characterized.
Bebear CM; Renaudin H; Charron A; Gruson D; Lefrancois M; Bebear C
Antimicrob Agents Chemother; 2000 Sep; 44(9):2557-60. PubMed ID: 10952617
[TBL] [Abstract][Full Text] [Related]
8. In vitro antimycoplasmal activities of rufloxacin and its metabolite MF 922.
Furneri PM; Bisignano G; Cerniglia G; Nicoletti G; Cesana M; Tempera G
Antimicrob Agents Chemother; 1994 Nov; 38(11):2651-4. PubMed ID: 7872762
[TBL] [Abstract][Full Text] [Related]
9. In-vitro activity of trovafloxacin, a new fluoroquinolone, against recent clinical isolates.
Felmingham D; Robbins MJ; Ingley K; Mathias I; Bhogal H; Leakey A; Ridgway GL; Grüneberg RN
J Antimicrob Chemother; 1997 Jun; 39 Suppl B():43-9. PubMed ID: 9222069
[TBL] [Abstract][Full Text] [Related]
10. Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibilities to reference macrolides, tetracyclines, and quinolones.
Kenny GE; Cartwright FD
Antimicrob Agents Chemother; 2001 Sep; 45(9):2604-8. PubMed ID: 11502536
[TBL] [Abstract][Full Text] [Related]
11. The in-vitro activity of grepafloxacin against Chlamydia spp., Mycoplasma spp., Ureaplasma urealyticum and Legionella spp.
Ridgway GL; Salman H; Robbins MJ; Dencer C; Felmingham D
J Antimicrob Chemother; 1997 Dec; 40 Suppl A():31-4. PubMed ID: 9484871
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of gemifloxacin (SB 265805; LB20304a) against human mycoplasmas.
Hannan PC; Woodnutt G
J Antimicrob Chemother; 2000 Mar; 45(3):367-9. PubMed ID: 10702559
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of sparfloxacin and other antimicrobial agents against genital pathogens.
Lefèvre JC; Bauriaud R; Gaubert E; Escaffre MC; Lareng MB
Chemotherapy; 1992; 38(5):303-7. PubMed ID: 1337506
[TBL] [Abstract][Full Text] [Related]
14. Susceptibility of Mycoplasma pneumoniae to several new quinolones, tetracycline, and erythromycin.
Kenny GE; Cartwright FD
Antimicrob Agents Chemother; 1991 Mar; 35(3):587-9. PubMed ID: 1903913
[TBL] [Abstract][Full Text] [Related]
15. In-vitro activity of grepafloxacin, a new fluoroquinolone, against mycoplasmas.
Bébéar CM; Renaudin H; Schaeverbeke T; Leblanc F; Bébéar C
J Antimicrob Chemother; 1999 May; 43(5):711-4. PubMed ID: 10382895
[TBL] [Abstract][Full Text] [Related]
16. Comparative in vitro activity of azithromycin, clarithromycin, erythromycin and lomefloxacin against Mycoplasma pneumoniae, Mycoplasma hominis and Ureaplasma urealyticum.
Renaudin H; Bébéar C
Eur J Clin Microbiol Infect Dis; 1990 Nov; 9(11):838-41. PubMed ID: 1964899
[TBL] [Abstract][Full Text] [Related]
17. Comparative in-vitro activity of sparfloxacin against genital pathogens.
Perea EJ; Aznar J; Garcia-Iglesias MC; Pascual A
J Antimicrob Chemother; 1996 May; 37 Suppl A():19-25. PubMed ID: 8737122
[TBL] [Abstract][Full Text] [Related]
18. Comparative in vitro activities of four new fluoroquinolones against Streptococcus pneumoniae determined by Etest.
Waites K; Brookings E; Nix S; Robinson A; Gray B; Swiatlo E
Int J Antimicrob Agents; 1998 Feb; 9(4):215-8. PubMed ID: 9573490
[TBL] [Abstract][Full Text] [Related]
19. Comparative in vitro susceptibilities and bactericidal activities of investigational fluoroquinolone ABT-492 and other antimicrobial agents against human mycoplasmas and ureaplasmas.
Waites KB; Crabb DM; Duffy LB
Antimicrob Agents Chemother; 2003 Dec; 47(12):3973-5. PubMed ID: 14638513
[TBL] [Abstract][Full Text] [Related]
20. Susceptibilities of genital mycoplasmas to the newer quinolones as determined by the agar dilution method.
Kenny GE; Hooton TM; Roberts MC; Cartwright FD; Hoyt J
Antimicrob Agents Chemother; 1989 Jan; 33(1):103-7. PubMed ID: 2712541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
